Physician profile
Dana E Campbell
NPI 1750698866
$1,141.46
in general payments reported to CMS, 2019-2025
15 companies · $263 in 2025
The $263 reported for 2025 was more than what a typical Surgical provider received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $79.30 · 2022: $288 · 2023: $335 · 2024: $177 · 2025: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $775.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $774.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $285.41 | 2021-2025 | |
| Abbvie INC. | $166.42 | 2023-2024 | |
| Novo Nordisk INC | $94.01 | 2023-2025 | Wegovy, Ozempic |
| Kestra Medical Technology Services, INC. | $89.23 | 2025 | Assure Wcd |
| Sanofi-Aventis U.S. LLC | $77.85 | 2021-2022 | |
| Amgen INC. | $75.53 | 2021-2024 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $67.95 | 2022-2024 | Lifevest |
| Merck Sharp & Dohme LLC | $65.84 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $53.95 | 2023 | Opsumit, Uptravi |
| Pfizer INC. | $45.28 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $38.64 | 2022-2023 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $32.35 | 2025 | Eliquis |
| Esperion Therapeutics, INC. | $20.06 | 2022 | |
| Janssen Biotech, INC. | $17.35 | 2025 | Tecvayli |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.